e-ISSN: Pending
Negative / Null Result ReportOpen accessDiseases of the endocrine glands. Clinical endocrinology

Evaluation of ketoconazole as a treatment for Cushing’s disease in a retrospective cohort

Camila Viecceli; Camila Viecceli; Ana Carolina Viana Mattos; Maria Carolina Bittencourt Costa; Rafael Borba de Melo; Ticiana da Costa Rodrigues; Ticiana da Costa Rodrigues; Ticiana da Costa Rodrigues · 2022 · Frontiers in Endocrinology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

ObjectiveThe first-line treatment for Cushing’s disease is transsphenoidal surgery, after which the rates of remission are 60 to 80%, with long-term recurrence of 20 to 30%, even in those with real initial remission. Drug therapies are indicated for patients without initial remission or with surgical contraindications or recurrence, and ketoconazole is one of the main available therapies. The objective of this study was to evaluate the safety profile of and the treatment response to ketoconazole in Cushing’s disease patients followed up at the endocrinology outpatient clinic of a Brazilian uni

Abstract by Camila Viecceli; Camila Viecceli; Ana Carolina Viana Mattos; Maria Carolina Bittencourt Costa; Rafael Borba de Melo; Ticiana da Costa Rodrigues; Ticiana da Costa Rodrigues; Ticiana da Costa Rodrigues, Frontiers in Endocrinology (2022) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.3389/fendo.2022.1017331